American Journal of Kidney Diseases
Volume 54, Issue 5 , Pages 902-911, November 2009

Association of LDL Cholesterol and Inflammation With Cardiovascular Events and Mortality in Hemodialysis Patients With Type 2 Diabetes Mellitus

  • Vera Krane, MD

      Affiliations

    • Department of Medicine I, Division of Nephrology, University of Würzburg, Germany
    • Corresponding Author InformationAddress correspondence to Vera Krane, MD, University of Würzburg, Department of Medicine, Division of Nephrology, University Hospital, Josef-Schneider-Str 2, D-97080 Würzburg, Germany
  • ,
  • Karl Winkler, MD

      Affiliations

    • Department of Medicine, Division of Clinical Chemistry, University Medical Center Freiburg, Freiburg, Germany
  • ,
  • Christiane Drechsler, MD

      Affiliations

    • Department of Medicine I, Division of Nephrology, University of Würzburg, Germany
  • ,
  • Jürgen Lilienthal

      Affiliations

    • DATAMAP GmbH, Freiburg, Germany
  • ,
  • Winfried März, MD

      Affiliations

    • Synlab Center of Laboratory Diagnostics, Heidelberg, Germany
  • ,
  • Christoph Wanner, MD

      Affiliations

    • Department of Medicine I, Division of Nephrology, University of Würzburg, Germany
  • ,
  • German Diabetes and Dialysis Study Investigators

Received 15 September 2008; accepted 15 June 2009. published online 27 September 2009.

Background

In the general population, C-reactive protein (CRP) in addition to low-density lipoprotein (LDL) cholesterol level is useful in predicting cardiovascular events. In hemodialysis patients, the additive value is unknown. The association between LDL cholesterol level and outcome previously was suggested to be inverse and confounded by inflammation.

Study Design

Prospective cohort study.

Setting & Participants

1,255 hemodialysis patients with type 2 diabetes mellitus randomly assigned to atorvastatin versus placebo in the German Diabetes Dialysis Study.

Predictors

Baseline LDL cholesterol level.

Outcomes & Measurements

Combined vascular end point (cardiac death, myocardial infarction, and stroke), mortality, myocardial infarction, sudden death, and stroke.

Results

During 4 years, 465 combined vascular events, 612 deaths, 160 sudden deaths, 200 myocardial infarctions, and 99 strokes occurred. Median LDL cholesterol level was 123 mg/dL. LDL cholesterol level (millimoles per liter and quartiles) was not predictive of outcome. This was analyzed further in patients with and without inflammation. In patients with inflammation (CRP level > 5 mg/L), the adjusted relative risk of combined vascular events was 29% greater compared with those without inflammation and a low LDL cholesterol level (LDL cholesterol ≤ 123 mg/dL). This was irrespective of whether LDL cholesterol level was low or high (hazard ratio [HR] for LDL < 123 mg/dL [HR for LDL≤123mg/dL], 1.29, with 95% confidence interval [CI], 0.98 to 1.70; HRLDL>123mg/dL, 1.29, with 95% CI, 0.99 to 1.69). Similar results were found for all-cause death (HRLDL≤123mg/dL, 1.47 [95% CI, 1.16 to 1.86]; HRLDL>123mg/dL, 1.48 [95% CI, 1.16 to 1.88]), sudden death (HRLDL≤123mg/dL, 1.98 [95% CI, 1.23 to 3.20]; HRLDL>123mg/dL, 1.66 [95% CI, 1.01 to 2.75]), and myocardial infarction (HRLDL≤123mg/dL, 1.74 [95% CI, 1.14 to 2.66]; HRLDL>123mg/dL, 1.54 [95% CI, 0.99 to 2.38]). In patients without inflammation, the respective risks did not differ significantly between patients with varying LDL cholesterol levels. However, there was a trend toward an increased risk of myocardial infarction (HRLDL>123mg/dL, 1.45 [95% CI, 0.95 to 2.21]) in patients with high compared with low LDL cholesterol levels. P values for the interaction between CRP and LDL cholesterol levels were 0.9 (composite vascular end point), 0.5 (mortality), 0.9 (sudden death), 0.09 (stroke), and 0.2 (myocardial infarction).

Limitations

Selected patient cohort, post hoc analysis.

Conclusion

Because CRP level more than LDL cholesterol level determined outcome, the value of regular LDL cholesterol measurements in long-term hemodialysis patients with type 2 diabetes needs reassessment.

Index Words: Low-density lipoprotein (LDL), C-reactive protein (CRP), hemodialysis, diabetes, mortality, cardiovascular events, outcome

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Originally published online as doi: 10.1053/j.ajkd.2009.06.029 on September 27, 2009.

 A list of the German Diabetes and Dialysis Study Investigators is available at www.nephrologie.uni-wuerzburg.de/4D/index_4d.htm.

PII: S0272-6386(09)00969-X

doi:10.1053/j.ajkd.2009.06.029

American Journal of Kidney Diseases
Volume 54, Issue 5 , Pages 902-911, November 2009